A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Recruiting now · Phase 1

Conditions studied: Locally Advanced, Recurrent or Metastatic Malignancies

In brief

This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.

Key facts

Study ID
NCT06390774
Run by
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
People needed
180
Starts
2024-05-30
Expected to finish
2027-02-01
Last updated by the study team
2024-10-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.